ABEO CFO Sells 15,000 Shares at $7.36 — Form 4 Report

Joseph Walter Vazzano, identified as the company's Chief Financial Officer, reported a sale of 15,000 shares of Abeona Therapeutics Inc. (ABEO) on 08/15/2025.

Rhea-AI Filing Summary

Joseph Walter Vazzano, identified as the company's Chief Financial Officer, reported a sale of 15,000 shares of Abeona Therapeutics Inc. (ABEO) on 08/15/2025. The shares were sold at a weighted-average price of $7.3572, with transaction prices ranging from $7.20 to $7.48. After the sale, Vazzano beneficially owned 462,666 shares. The Form 4 was filed by a single reporting person and is signed by Vazzano on the transaction date.

Positive

• None.

Negative

• Insider sale of 15,000 common shares by the CFO on 08/15/2025 at a weighted-average price of $7.3572

Insights

Securities Analyst

TL;DR: Insider sale of 15,000 shares by the CFO; modest change in holdings, limited immediate signal to investors.

The filing discloses a single non-derivative sale by the Chief Financial Officer of 15,000 common shares at a weighted-average price of $7.3572 on 08/15/2025. Post-transaction ownership is 462,666 shares, reported as direct ownership. The disclosure is routine and complies with Section 16 reporting requirements. Without context on historical selling patterns, percentage ownership or company share count, the transaction alone provides limited insight into executive intent or material corporate developments.

Corporate Governance Expert

TL;DR: Timely Form 4 filing shows compliance; transaction appears administrative rather than a material governance event.

The report is properly executed and signed by the reporting person, indicating adherence to disclosure rules. The explanation clarifies the reported price is a weighted average across multiple trades between $7.20 and $7.48. There is no indication of a Rule 10b5-1 plan or other dispositive agreement noted on the form, and no amendment flag is present. As presented, this is a routine insider disposition rather than a governance action that would materially alter board composition or company control.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Vazzano Joseph Walter

Role Chief Financial Officer

Sold 15,000 shs ($110K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,000	$7.3572	$110K

Holdings After Transaction: Common Stock — 462,666 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.48 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who filed the Form 4 for ABEO?

Joseph Walter Vazzano, identified as the company's Chief Financial Officer, signed the Form 4 on 08/15/2025.

What transaction was reported on the ABEO Form 4 dated 08/15/2025?

A sale of 15,000 shares of Abeona Therapeutics Inc. common stock reported as transaction code S.

At what price were the ABEO shares sold by the insider?

The shares were sold at a weighted-average price of $7.3572, with trades ranging from $7.20 to $7.48.

How many ABEO shares did the reporting person own after the transaction?

The reporting person beneficially owned 462,666 shares following the reported sale.

Was the Form 4 filed by multiple reporting persons?

No. The form indicates it was filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/15/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S		15,000	D	$7.3572(1)	462,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.48 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.